MedTrace Logo

Renal Transplantation and Raltegravir in HIV-Infected Patients

NCT01453192 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-04-13

No results posted yet for this study

Summary

The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.

Conditions

  • HIV-1 Infection
  • Chronic Renal Insufficiency

Interventions

DRUG

Raltegravir

Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease

Sponsors & Collaborators

Principal Investigators

  • Philippe GRIMBERT, MD · CHU Henri-Mondor

  • Dominique COSTAGLIOLA, PHD · INSERM U943

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01453192 on ClinicalTrials.gov